Radiation via Monoclonal Antibodies
| Property | Information |
|---|---|
| Drug Name | Radiation via Monoclonal Antibodies |
| Overview | Radiation via monoclonal antibodies is an experimental targeted treatment for glioblastoma and other high-grade gliomas, utilizing radioactive isotopes linked to antibodies that target tumor-specific antigens to enhance therapeutic efficacy while reducing collateral damage to healthy tissue. Early clinical trials have shown promising median survival benefits, but further research is needed to fully assess its safety and effectiveness, as it is currently not FDA-approved. |
| FDA Approval | No |
| Used for | Glioblastoma and potentially other high-grade glioma tumors |
| Clinical Trial Phase | Early to mid-stage clinical trials |
| Clinical Trial Explanation | Not specified |
| Common Side Effects | Varies; can include fatigue, headache, localized reactions at infusion site |
| OS without | Standard treatments for GBM typically result in a median overall survival of 14-17 months |
| OS with | Early trials show median survival times from 56 weeks for recurrent GBM to up to 24.9 months in certain cohorts |
| PFS without | Median progression-free survival with standard treatments is about 6-9 months for GBM |
| PFS with | Some studies report mean progression-free survival up to 17.2 months, compared to 4-10 months for other treatments |
| Usefulness Rating | 3 |
| Usefulness Explanation | Shows promise for targeted radiation delivery to tumor cells with potential for sparing normal tissue and reducing side effects, but more research is needed for a definitive assessment |
| Toxicity Level | 3 |
| Toxicity Explanation | Potential risks are present and may be comparable to or slightly less than traditional treatments, with concerns about toxicity under investigation |
From Ben Williams Book: Radiation therapy via monoclonal antibodies introduces a targeted approach to delivering radiation to glioblastoma cells. This method involves attaching radioactive isotopes, such as iodine-131, to monoclonal antibodies that target specific antigens present on tumor cells but not on normal brain cells. The approach aims to maximize the therapeutic impact on the tumor while minimizing exposure and damage to surrounding healthy brain tissue. Duke University has been a pioneer in applying this technique. The major challenges include overcoming the blood-brain barrier and navigating the immunosuppressive tumor microenvironment. Early clinical trials have shown promising outcomes, with certain patient cohorts experiencing extended median survival times. However, the effectiveness and safety of this treatment are still under active investigation, highlighting the need for ongoing research and clinical trials to fully understand its potential and limitations.Property "Has original text" (as page type) with input value "Radiation therapy via monoclonal antibodies introduces a targeted approach to delivering radiation to glioblastoma cells. This method involves attaching radioactive isotopes, such as iodine-131, to monoclonal antibodies that target specific antigens present on tumor cells but not on normal brain cells. The approach aims to maximize the therapeutic impact on the tumor while minimizing exposure and damage to surrounding healthy brain tissue. Duke University has been a pioneer in applying this technique. The major challenges include overcoming the blood-brain barrier and navigating the immunosuppressive tumor microenvironment. Early clinical trials have shown promising outcomes, with certain patient cohorts experiencing extended median survival times. However, the effectiveness and safety of this treatment are still under active investigation, highlighting the need for ongoing research and clinical trials to fully understand its potential and limitations." contains invalid characters or is incomplete and therefore can cause unexpected results during a query or annotation process.
